Skip to content

Assessing Insulin Sensitivity and Diabetes Risk in Childhood Cancer Survivors Treated With Abdominal Irradiation

Assessing Insulin Sensitivity and Diabetes Risk in Childhood Cancer Survivors Treated With Abdominal Irradiation: A Pilot Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02248779
Enrollment
42
Registered
2014-09-25
Start date
2014-09-22
Completion date
2019-10-09
Last updated
2019-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Cancer Survivors Treated With Abdominal Radiation

Keywords

Diabetes Risk, 14-202

Brief summary

The purpose of this study is to better understand the risk factors and causes of diabetes in people who received radiation to the abdomen as children. The investigators hope this information will allow them to improve how they screen people at risk for diabetes and how they treat patients in the future.

Interventions

None listed

Sponsors

Memorial Sloan Kettering Cancer Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Diagnosis of childhood cancer between 0-21 years of age * Prior treatment with abdominal radiation at MSKCC * Two or more years from completion of therapy * Records of cancer diagnosis and treatment (including radiation records) available

Exclusion criteria

* Known diagnosis of diabetes * Previous treatment with any radiation impacting the brain (cranial radiation, craniospinal radiation, total body irradiation) * Neurocognitive deficits that impair ability to give informed consent or assent * Patients predicted to have difficult intravenous access, who will likely require multiple venipuncture attempts

Design outcomes

Primary

MeasureTime frameDescription
characterize β cell function2 yearswe will be able to estimate the proportion of patients with abnormalities of insulin sensitivity or β cell function, as assessed by the OGTT, to within ± 0.14.
insulin sensitivity2 yearswe will be able to estimate the proportion of patients with abnormalities of insulin sensitivity or β cell function, as assessed by the OGTT, to within ± 0.14.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026